XML 33 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share and Shareholders' Equity
9 Months Ended
Sep. 29, 2018
Earnings Per Share [Abstract]  
Earnings per share and shareholders' equity
EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in the basic and diluted earnings per share ("EPS") calculation is as follows (in millions):
 
Three Months Ended
 
Nine Months Ended
 
September 29,
2018
 
September 30,
2017
 
September 29,
2018
 
September 30,
2017
Numerator:
 
 
 
 
 
 
 
Net income (loss)
$
(67.5
)
 
$
44.5

 
$
49.6

 
$
46.4

 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding for basic EPS
137.4

 
141.3

 
138.5

 
142.5

Dilutive effect of share-based awards*

 
0.4

 
0.5

 
0.3

Weighted average shares outstanding for diluted EPS
137.4

 
141.7

 
139.0

 
142.8

 
 
 
 
 
 
 
 
Anti-dilutive share-based awards excluded from computation of diluted EPS

 
1.0

 
1.2

 
0.8



* In the period of a net loss, diluted shares equal basic shares.

Shareholders' Equity

Shares

We issued shares related to the exercise and vesting of share-based compensation as follows:
Three Months Ended
 
Nine Months Ended
September 29,
2018
 
September 30,
2017
 
September 29,
2018
 
September 30,
2017
90,000

 
99,800

 
217,000

 
146,100



Share Repurchases

In October 2015, the Board of Directors approved a three-year share repurchase plan of up to $2.0 billion. During the three and nine months ended September 29, 2018, we repurchased 1.8 million and 5.1 million ordinary shares at an average repurchase price of $73.46 and $77.93 per share, for a total of $135.0 million and $400.0 million, respectively. During the three and nine months ended September 30, 2017, we repurchased 1.9 million and 2.7 million ordinary shares at an average repurchase price of $71.73 and $71.72 per share, for a total of $133.3 million and $191.5 million, respectively. Given the expiration of the previous authorization, in October 2018, the Board of Directors authorized up to $1.0 billion of shares repurchase authorization. This authorization has no expiration date.